Standard treatment for hepatitis C is 48 weeks of a combination of two drugs, peginterferon alfa-2a plus the antiviral agent ribavirin. The treatment cures roughly 40 percent of who undergo it; for those who fail to respond, the only backup is a second round of therapy with the very same treatment.
The results of this study, appearing in the New England Journal of Medicine, suggest that telaprevir, a protease inhibitor that works by blocking an enzyme the hepatitis C virus needs to replicate itself, may greatly enhance many patients' chance of a cure, according to John McHutchison, MD, associate director for research for the DCRI and the lead author of the study.
The findings come from a DCRI-coordinated, multinational study of 453 patients who had failed to fully respond to initial treatment. All participants had the most common form of the virus, genotype 1, generally regarded as the most difficult type of hepatitis C to cure.
Investigators randomized the patients into one of four treatment groups. All participants received either peginterferon or peginterferon plus ribavirin for 24 or 48 weeks. Researchers added the experimental drug telaprevir to three of the regimens for 12 or 24 weeks. Patients in a fourth arm of the study received a placebo plus peginterferon and ribavirin.
Telaprevir is made by Vertex Pharmaceuticals Incorporated, which funded the study, formally known as Protease Inhibition of Viral Evaluation 3 (PROVE3).
Researchers measured the amount of virus in the patients' blood at multiple points during the course of their therapy and then checked on their viral load six months after they had taken their last treatment. Those who did not have any detectable virus in their blood at that point were considered cured.
Investigators found that the addition of telaprevir to a treatment plan significantly improved cure rates across the board. "Fifty-two percent of patients who had originally failed to respond to standard treatment were cured of their disease when we added telaprevir to a retreatment regimen consisting of peginterferon alfa-2a and ribavirin" said McHutchison. "This is a major development in the field and may represent the single most significant efficacy finding in the treatment of prior non-responders."
Researchers also found that 24 percent of patients who received telaprevir and peginterferon – but no ribavirin – were virus-free at the end of the 6-month post- treatment period, a finding that confirms that ribavirin is a critical component of effective treatment, according to McHutchison. In contrast, only 14 percent of those who received standard treatment were virus-free at six months. Those in the latter group were offered treatment with telaprevir, peginterferon and ribavirin in a later study.
Data analysis also revealed an association between patients' prior experience with treatment and response to retreatment: Patients who had originally responded to standard therapy but who relapsed were more likely to have a sustained response to telaprevir than were original non-responders.
The benefit of adding telaprevir, however, was offset somewhat by significant side effects. About half of those receiving telaprevir developed a rash, and 5 percent of those who did so had to stop therapy because the rash was severe. Patients who received telaprevir-based therapy were also more likely to discontinue therapy (50 of 339, or 15 percent) than were patients who received standard therapy (5 of 114, or 4 percent).
"While it is true that patients receiving all three drugs were more likely to experience side effects, especially rash and anemia, the benefit of the regimen can be substantial," said McHutchison. "Adding telaprevir to standard treatment for hepatitis C is very helpful to large numbers of patients who originally failed to fully respond to previous treatment."
A phase III trial further evaluating telaprevir retreatment strategies for patients who didn't respond to initial therapy is currently under way.
Colleagues from Duke who contributed to the study include Andrew Muir and Jyotsna Garg. Other members of the study team include Michael Manns, from the Medical School of Hanover; Norah Terrault, University of California at San Francisco; Ira Jacobson, Weill Cornell Medical College; Nezam Afdhal, Beth Israel Deaconess Medical Center; Jenny Heathcote, University of Toronto; Stefan Zeuzem, Johann Wolfgang Goethe University Medical Center; Hendrik Reesnik, the Academic Medical Center, Amsterdam; Adrian DiBisceglie, St. Louis School of Medicine and Mohammad Bsharat, Shelley George, Robert Kaufman and Nathalie Adda, from Vertex Pharmaceuticals Incorporated.
McHutchison has received research support from Vertex and has been paid as an academic advisor and scientific consultant for the company.
Michelle Gailiun | EurekAlert!
Investigators may unlock mystery of how staph cells dodge the body's immune system
22.09.2017 | Cedars-Sinai Medical Center
Monitoring the heart's mitochondria to predict cardiac arrest?
21.09.2017 | Boston Children's Hospital
Plants and algae use the enzyme Rubisco to fix carbon dioxide, removing it from the atmosphere and converting it into biomass. Algae have figured out a way to increase the efficiency of carbon fixation. They gather most of their Rubisco into a ball-shaped microcompartment called the pyrenoid, which they flood with a high local concentration of carbon dioxide. A team of scientists at Princeton University, the Carnegie Institution for Science, Stanford University and the Max Plank Institute of Biochemistry have unravelled the mysteries of how the pyrenoid is assembled. These insights can help to engineer crops that remove more carbon dioxide from the atmosphere while producing more food.
A warming planet
Our brains house extremely complex neuronal circuits, whose detailed structures are still largely unknown. This is especially true for the so-called cerebral cortex of mammals, where among other things vision, thoughts or spatial orientation are being computed. Here the rules by which nerve cells are connected to each other are only partly understood. A team of scientists around Moritz Helmstaedter at the Frankfiurt Max Planck Institute for Brain Research and Helene Schmidt (Humboldt University in Berlin) have now discovered a surprisingly precise nerve cell connectivity pattern in the part of the cerebral cortex that is responsible for orienting the individual animal or human in space.
The researchers report online in Nature (Schmidt et al., 2017. Axonal synapse sorting in medial entorhinal cortex, DOI: 10.1038/nature24005) that synapses in...
Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...
Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!
When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...
For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.
Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...
19.09.2017 | Event News
12.09.2017 | Event News
06.09.2017 | Event News
22.09.2017 | Life Sciences
22.09.2017 | Medical Engineering
22.09.2017 | Physics and Astronomy